Other
Exercise
0
Pipeline Programs↗
19
Active Trials↗
13
Companies Involved↗
Exercise is an early-stage landscape with 0 programs across 13 companies. The most active players are Boehringer Ingelheim, Mezzion Pharma Co. Ltd, Tenax Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
105
clinical trials
Completed68 · 65%
Unknown status13 · 12%
Recruiting11 · 10%
Terminated5 · 5%
Not yet recruiting4 · 4%
Active, not recruiting3 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
105 trials
U-LABA/ICS Effects on Exercise Performance, Indacaterol
Recruiting·—·N/A·NCT06067100·30 enrolled
Bronchodilators and Lung Mechanics During Exercise in COPD
Recruiting·—·Phase 4·NCT06825013·25 enrolled
U-LABA/ICS Effects on Exercise Performance, Vilanterol
Recruiting·—·N/A·NCT06066606·30 enrolled
Kinesthetic Exercises on Adults
Active, not recruiting·—·N/A·NCT07417748·40 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)